Hussman Strategic Advisors Inc. Has $3.26 Million Stock Holdings in Pacira BioSciences, Inc. $PCRX

Hussman Strategic Advisors Inc. increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 20.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,000 shares of the company’s stock after purchasing an additional 21,000 shares during the quarter. Pacira BioSciences makes up about 0.8% of Hussman Strategic Advisors Inc.’s portfolio, making the stock its 16th largest holding. Hussman Strategic Advisors Inc. owned about 0.29% of Pacira BioSciences worth $3,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in PCRX. Doma Perpetual Capital Management LLC raised its position in Pacira BioSciences by 49.7% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock worth $69,613,000 after purchasing an additional 897,255 shares during the period. Impax Asset Management Group plc raised its position in Pacira BioSciences by 25.0% in the 4th quarter. Impax Asset Management Group plc now owns 750,027 shares of the company’s stock worth $19,411,000 after purchasing an additional 150,000 shares during the period. Assenagon Asset Management S.A. raised its position in Pacira BioSciences by 87.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,143 shares of the company’s stock worth $11,262,000 after purchasing an additional 202,773 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in Pacira BioSciences by 171.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 138,105 shares of the company’s stock worth $3,574,000 after purchasing an additional 87,210 shares during the period. Finally, Gagnon Securities LLC raised its position in Pacira BioSciences by 22.1% in the 3rd quarter. Gagnon Securities LLC now owns 449,717 shares of the company’s stock worth $11,589,000 after purchasing an additional 81,364 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 4,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $20.81, for a total transaction of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares in the company, valued at $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shawn Cross sold 12,941 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total transaction of $325,595.56. Following the transaction, the chief financial officer owned 105,341 shares in the company, valued at $2,650,379.56. This represents a 10.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,261 shares of company stock worth $785,850 over the last 90 days. 6.40% of the stock is owned by company insiders.

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock opened at $24.44 on Friday. The firm has a market cap of $961.23 million, a PE ratio of 203.68 and a beta of 0.32. Pacira BioSciences, Inc. has a 12-month low of $18.80 and a 12-month high of $27.64. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54. The company’s fifty day simple moving average is $23.31 and its two-hundred day simple moving average is $23.15.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $177.38 million during the quarter, compared to the consensus estimate of $171.80 million. Pacira BioSciences had a return on equity of 9.99% and a net margin of 0.70%.Pacira BioSciences’s revenue was up 5.0% on a year-over-year basis. During the same period last year, the business earned $0.65 EPS. As a group, equities analysts expect that Pacira BioSciences, Inc. will post 1.85 EPS for the current year.

Pacira BioSciences News Summary

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Needham & Company raised its price target to $32 and maintained a Buy rating — this implies ~31.7% upside from the recent price and serves as a strong bullish analyst catalyst for investors focused on upside potential. Needham PT Raise
• Positive Sentiment: Q1 results beat expectations: revenue of ~$177M (+5% YoY) and EPS of $0.60 topped consensus, driven by commercial portfolio growth (including EXAPAREL volume growth). That operational beat supports near-term revenue trajectory and validates current demand. Q1 Press Release
• Positive Sentiment: Pipeline progress: Pacira advanced PCRX-201 into Phase II and completed enrollment in a Phase 3 shoulder OA study for ZILRETTA, keeping multiple clinical milestones on the calendar that could drive medium-term upside if readouts are positive. Pipeline & Guidance Summary
• Neutral Sentiment: Royal Bank of Canada raised its price target from $22 to $24 but kept a “sector perform” rating — the PT is only marginally changed relative to the market and signals a cautious stance despite the bump. RBC PT Update
• Neutral Sentiment: Earnings materials and the call highlighted “strong product growth” and provided detail on product mix and market dynamics — helpful context but not an immediate directional shock. Earnings Call Highlights
• Negative Sentiment: FY2026 revenue guidance of $745M–$770M sits slightly under consensus (~$761.5M at the time of the news), leaving the guidance a bit cautious and a potential near-term headwind if investors expected a clearer upside beat. Guidance Article
• Negative Sentiment: Overall market reaction is negative today (heavier-than-normal volume), reflecting investor caution as they reconcile the mixed signals: solid quarter and pipeline news vs. conservative-to-in-line guidance and at least one cautious analyst stance. Market Data

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada lifted their target price on shares of Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $29.40.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.